EcoDrugPlus

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSPNYG00000010629
Gene Symbol: GRIK5
3 Cross references
229 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSPNYG00000022315
Gene Symbol: GRIK5
3 Cross references
232 Possible Orthologues:

Glutamate Metabotropic Receptor 2

Ensembl ID : ENSPNYG00000006561
Gene Symbol: GRM2
3 Cross references
207 Possible Orthologues:

Glutamate Metabotropic Receptor 3

Ensembl ID : ENSPNYG00000007571
Gene Symbol: GRM3
3 Cross references
215 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSPNYG00000005053
Gene Symbol: GRM4
3 Cross references
207 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSPNYG00000018018
Gene Symbol: GRM4
3 Cross references
196 Possible Orthologues:

Glutamate Metabotropic Receptor 5

Ensembl ID : ENSPNYG00000014493
Gene Symbol: GRM5
3 Cross references
214 Possible Orthologues:

Glutamate Receptor 1-Like

Ensembl ID : ENSPNYG00000004488
Gene Symbol: LOC102204572
3 Cross references
247 Possible Orthologues:

Glutamate Receptor 2-Like

Ensembl ID : ENSPNYG00000016977
Gene Symbol: LOC102208943
3 Cross references
242 Possible Orthologues:

Glutamate Receptor 3

Ensembl ID : ENSPNYG00000019554
Gene Symbol: LOC102212429
3 Cross references
251 Possible Orthologues:

Glutamate Receptor 4

Ensembl ID : ENSPNYG00000011041
Gene Symbol: LOC102213250
3 Cross references
249 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 1

Ensembl ID : ENSPNYG00000018102
Gene Symbol: LOC102201489
3 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).